



Docket No. 20 FWC

GP1644/11
RECEIVED

APR 25 2000

TECH CENTER 1600/2900

p#22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang et al.

Serial No: 08/867,612

Examiner: Gambel, P.

Filed: June 2, 1997

Group: 1644

For: **Methods For The Treatment Of Inflammatory Joint Disease**

Assistant Commissioner for Patents
Washington, D.C. 20231


CERTIFICATE OF MAILING

Date of Deposit: April 10, 2000

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement
- ☒ Forty Seven (47) Cited References
- ☒ Form PTO-1449
- ☒ Check
- ☒ Return postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.



Carolyn Wise

Alexion Pharmaceuticals, Inc.
25 Science Park, Suite 360
New Haven, CT. 06511



Docket: 20 FWC

RECEIVED

APR 25 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Wang et al.

Serial No: 08/867,612

Examiner: Gambel, P.

Filed: June 2, 1997

Group Art Unit: 1644

For: **Methods For The Treatment Of Inflammatory Joint Disease**

Assistant Commissioner of Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

04/19/2000 AMCHAMME 00000002 08867612

01 FC:126

240.00 OP

() This information disclosure statement is being filed within three
(3) months of the filing date of this application.

() This information disclosure statement is being filed within three
(3) months of the date of entry of the national stage as set forth in
37 C.F.R. § 1.491 in an international application.

() To the best of Applicant(s) knowledge, this information
disclosure statement is being filed before the date of mailing of a
first Office Action in connection with this case.

() Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

() Enclosed is a petition under 37 C.F.R. §1.97 (d)

() Please charge the petition fee of \$130.00 required under
37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.


(x) As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s)
knowledge, this information disclosure statement is being filed before
either the mailing of a final action under 37 C.F.R. §1.113 or the
mailing of a notice of allowance under 37 C.F.R. §1.113, and is
accompanied by the \$240.00 fee as provided for in 37 C.F.R. §1.17(p).

() Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to
Deposit Account No. 01-0483.

(X) Please charge any deficiency as well as any other fee(s) which
may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time
during the pendency of this application, or credit any overpayment of
such fee(s) to Deposit Account 01-0483. Also, in the event any
extensions of time for responding are required for the pending
application(s), please treat this paper as a petition to extend time as
required and charge Deposit Account No. 01-0483 therefor. **TWO**
COPIES OF THIS SHEET ARE ENCLOSED.

Early and favorable consideration of the case is respectfully
requested.

Dated: April 10, 00



Mark Farber
Registration No. 34,159
Attorney for the Applicants

Alexion Pharmaceuticals, Inc.
25 Science Park, Suite 360
New Haven, CT. 06511
(203) 776-1790